ArticleThe Laryngoscope2026
Machine Learning-Based Risk Stratification Tool for Hearing Loss in High-Risk Neonates.
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to develop and evaluate a machine learning-based risk stratification tool for predicting hearing loss in high-risk neonates using clinical risk factors to support targeted early identification.
methodsA total of 270 infants, 105 with hearing loss, 165 with normal hearing who had passed initial screening but possessed clinical risk factors were retrospectively analyzed. Clinical variables included prematurity, low birth weight, hyperbilirubinemia, phototherapy, NICU stay duration, and family history. Five models (Random Forest, XGBoost, CatBoost, K-nearest neighbors, and Logistic Regression) were developed using an 80/20 train-test split and stratified 5-fold cross-validation. Additionally, a web-based clinical decision support tool was developed using the Streamlit framework to provide real-time risk assessment.
resultsThe XGBoost model achieved the highest performance with 85.2% accuracy and an AUC of 87.1%. SHAP analysis identified NICU stay duration and positive family history as the most influential predictors for neonatal hearing loss.
conclusionMachine learning models, particularly XGBoost, provide robust risk stratification for high-risk neonates. Rather than replacing universal screenings, these tools can complement existing programs by identifying high-risk infants who require prioritized diagnostic follow-up and closer clinical monitoring. The developed web application (available at https://newbornhearing.streamlit.app/) offers a practical interface for clinical use. LEVEL OF EVIDENCE: 3:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.